2 results
Approved WMOCompleted
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A in patients with prodromal or mild Alzheimer*s disease (AD), ages 50*80, who are amyloid positive by cerebrospinal fluid (CSF) or amyloid positron…
Approved WMOPending
Main objective: Part A: To evaluate the safety and tolerability of AL102 in subjects withprogressing desmoid tumorsPart B: To evaluate effects of AL102 on disease progression in subjectswith progressing desmoid tumorsOLE: To evaluate the safety and…